| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
113,172,000 |
| Market
Cap: |
357.62(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.33 - $10.92 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 5.3 |
| Insider 6 Months : 6.5 |
| Insider 3/6 Months : 12.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. Co. has three clinical-stage ex vivo lentiviral vector. These include programs for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
10,000 |
20,000 |
61,099 |
61,099 |
| Total Buy Value |
$34,400 |
$68,500 |
$269,265 |
$269,265 |
| Total People Bought |
1 |
1 |
3 |
3 |
| Total Buy Transactions |
1 |
2 |
4 |
4 |
| Total Shares Sold |
11,553 |
75,921 |
133,455 |
618,691 |
| Total Sell Value |
$34,463 |
$256,183 |
$758,501 |
$13,543,531 |
| Total People Sold |
4 |
4 |
6 |
9 |
| Total Sell Transactions |
4 |
14 |
32 |
64 |
| End Date |
2025-11-09 |
2025-08-08 |
2025-02-07 |
2024-02-08 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bjork Elisabeth |
|
• • – |
2026-01-02 |
4 |
B |
$3.44 |
$34,400 |
D/D |
10,000 |
50,000 |
0.01 |
-13% |
|
| Militello John |
See Remarks |
• • – |
2025-11-18 |
4 |
S |
$2.98 |
$3,240 |
D/D |
(1,086) |
65,920 |
|
-2% |
|
| Wilson Martin |
General Counsel |
• • – |
2025-11-18 |
4 |
S |
$2.98 |
$4,910 |
D/D |
(1,646) |
383,816 |
|
-2% |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2025-11-18 |
4 |
S |
$2.98 |
$7,592 |
D/D |
(2,545) |
299,064 |
|
-2% |
|
| Shah Gaurav |
CEO |
• • – |
2025-11-18 |
4 |
S |
$2.98 |
$18,721 |
D/D |
(6,276) |
778,296 |
|
-2% |
|
| Wilson Martin |
General Counsel |
• • – |
2025-11-03 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
385,462 |
|
- |
|
| Militello John |
See Remarks |
• • – |
2025-10-14 |
4 |
S |
$3.96 |
$114,581 |
D/D |
(28,918) |
67,006 |
|
30% |
|
| Rizvi Syed Ali-Aamir |
Chief Medical Officer |
• • – |
2025-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
345,911 |
345,911 |
|
- |
|
| Fong Peter |
|
• • – |
2025-09-24 |
4 |
A |
$0.00 |
$0 |
D/D |
53,333 |
53,333 |
|
- |
|
| Wong Roderick |
See Remarks |
– • • |
2025-09-19 |
4 |
D |
$3.11 |
$3,415,500 |
I/I |
(1,100,000) |
18,188,457 |
|
- |
|
| Wong Roderick |
See Remarks |
– • • |
2025-09-19 |
4 |
OE |
$17.81 |
$41,866,016 |
I/I |
1,100,000 |
18,247,457 |
|
- |
|
| Wilson Martin |
General Counsel |
• • – |
2025-09-08 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
285,462 |
|
- |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2025-09-08 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
301,609 |
|
- |
|
| Militello John |
See Remarks |
• • – |
2025-09-08 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
95,924 |
|
- |
|
| Bjork Elisabeth |
|
• • – |
2025-08-27 |
4 |
B |
$3.41 |
$34,100 |
D/D |
10,000 |
40,000 |
0.01 |
7% |
|
| Wilson Martin |
General Counsel |
• • – |
2025-08-19 |
4 |
S |
$3.00 |
$1,762 |
D/D |
(588) |
135,462 |
|
-20% |
|
| Militello John |
See Remarks |
• • – |
2025-08-19 |
4 |
S |
$3.00 |
$1,082 |
D/D |
(361) |
55,924 |
|
-20% |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2025-08-19 |
4 |
S |
$3.00 |
$2,412 |
D/D |
(805) |
221,609 |
|
-20% |
|
| Wilson Martin |
General Counsel |
• • – |
2025-08-18 |
4 |
S |
$3.07 |
$3,077 |
D/D |
(1,004) |
136,050 |
|
-16% |
|
| Militello John |
See Remarks |
• • – |
2025-08-18 |
4 |
S |
$3.07 |
$2,142 |
D/D |
(699) |
56,285 |
|
-16% |
|
| Shah Gaurav |
CEO |
• • – |
2025-08-18 |
4 |
D |
$3.05 |
$6,814 |
D/D |
(2,234) |
784,572 |
|
- |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2025-08-18 |
4 |
S |
$3.07 |
$5,149 |
D/D |
(1,680) |
222,414 |
|
-16% |
|
| Militello John |
See Remarks |
• • – |
2025-08-14 |
4 |
S |
$3.02 |
$21,263 |
D/D |
(7,043) |
56,984 |
|
-17% |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2025-08-14 |
4 |
S |
$3.02 |
$33,695 |
D/D |
(11,161) |
224,094 |
|
-17% |
|
| Wilson Martin |
General Counsel |
• • – |
2025-08-14 |
4 |
S |
$3.02 |
$36,557 |
D/D |
(12,109) |
137,054 |
|
-17% |
|
208 Records found
|
|
Page 1 of 9 |
|
|
0.16 (5.33%) 
